Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 629-767-5 | CAS number: 1228186-18-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- from 2003-09-17 to 2003-10-10
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study, although OECD 423 version of 1996 rather than the updated version of 2001.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 004
- Report date:
- 2004
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- N-[2-(piperazin-1-yl)ethyl]C18-unsatured-alkylamide
- EC Number:
- 629-767-5
- Cas Number:
- 1228186-18-2
- Molecular formula:
- No molecular formula
- IUPAC Name:
- N-[2-(piperazin-1-yl)ethyl]C18-unsatured-alkylamide
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: 8 weeks old
- Weight at study initiation: 270 ± 10 g for the males, and 222 ± 3 g for the females
- Fasting period before study: overnight pre-testing fasting
- Housing: in polycarbonate cages with stainless steel lids. Each cage contained 1 to 7 rats of the same sex during acclimation, and 3 rats of the same sex and group during the treatment period.
- Diet : ad libitum
- Water: ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±2°C
- Humidity (%): 30 to 70%
- Air changes (per hr): 12 hour light/dark cycle
- Photoperiod (hrs dark / hrs light): 12 air changes per hour.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Concentrations in vehicle: 20 and 200 mg/ml
- Amount of vehicle (if gavage): 10 ml/kg
- Justification for choice of vehicle: solubility
MAXIMUM DOSE VOLUME APPLIED: 10 ml/kg
CLASS METHOD
- Rationale for the selection of the starting dose:
the dose-level used as the starting dose was selected from one of the 3 fixed levels: 25, 200 or 2000 mg/kg bw. As no information on the toxic potential of the test item was available, for animal welfare reasons, the starting dose of 200 mg/kg bw was chosen - Doses:
- 200 and 2000 mg/kg/bw
- No. of animals per sex per dose:
- 3 males and females given 200 mg/kg bw, 3 males given 2000 mg/kg bw
- Control animals:
- other: Historical data of control animals dosed by oral route
- Details on study design:
- - Duration of observation period following administration: 14 days after first day of dosing (D1)
- Frequency of observations and weighing: the animals were observed frequently during the hours following administration of the test item, for detection of possible treatment-related clinical signs. Thereafter, observation of the animals was made at least once a day. Type, time of onset and duration of clinical signs were recorded for each animal individually. The animals were weighed individually just before administration of the test item on day 1 and then on days 8 and 15.
- Necropsy of survivors performed: yes
Results and discussion
Effect levels
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 200 - 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: toxicity is comparable in females
- Mortality:
- No mortality occurred at the 200 mg/kg dose in both sexes. At the 2000 mg/kg dose-level, 2out of 3 males were found dead on day 2 or 3.
- Clinical signs:
- other: At 200 mg/kg: Hypoactivity, piloerection and dyspnea, together with hypersalivation on day 1, were observed in all males on days 1 and 2. In all females, only hypoactivity and piloerection were noted on day 1. At 2000 mg/kg: Hypoactivity, piloerection an
- Gross pathology:
- Macroscopic examination of the main organs of the animals revealed no apparent abnormalities.
Applicant's summary and conclusion
- Interpretation of results:
- other: Toxicity category 4 / Harmful
- Remarks:
- Criteria used for interpretation of results: other: CLP (Reg. 1272/2008/EC) + expert judgement and Directive 67/548/EEC
- Conclusions:
- The oral LD50 of the test item was comprised between 200 and 2000 mg/kg in rats, with a LD50 cut-off of 1000 mg/kg.
- Executive summary:
The acute oral toxicity of the test item was evaluated in rats according to OECD guideline 423 (1996) and EU method B.1tris. The study was conducted in compliance with the principles of Good Laboratory Practice Regulations.
The test item was prepared in corn oil and was administered by oral route (gavage), under a volume of 10 mL/kg, to groups of three fasted Sprague-Dawley rats. Males were used in the initial step starting with a dose-level of 200 mg/kg bw. As no deaths occured, another assay was
carried out on 3 other males at 2000 mg/kg bw . After this second assay as 2/3 animals died, another assay was carried out on 3 females at the next lower dose-level of 200 mg/kg bw.At each step, clinical signs, mortality and body weight gain were checked for a period of up to 14 days following the single administration of the test item. All animals were subjected to necropsy.
At the 200 mg/kg bw dose-level, no mortality occured. Hypoactivity, piloerection and dyspnea, together with hypersalivation on day 1, were observed in all males on days 1 and 2. In all females, only hypoactivity and piloerection were noted on day 1. When compared to historical control data, the body weight gain of the animals was not affected by treatment with the test item. At necropsy, no apparent abnormalities were observed in any animal.
At the 2000 mg/kg bw dose-level, 2out of 3 males were found dead on day 2 or 3. Hypoactivity, piloerection and dyspnea were recorded prior to death. In the surviving male, the same clinical signs, together with swollen abdomen and loud breathing on day 3, were observed from day 1 up to day 3; loud breathing persisted until day 12. The body weight gain of the surviving male given 2000 mg/kg was reduced during the first week of the study when compared to historical control animals. At necropsy, no apparent abnormalities were observed.
Under these experimental conditions, the oral LD50of the test item was comprised between 200 and 2000 mg/kg in male rats. Toxicity was comparable in females. The LD50 cut-off is established at 1000 mg/kg.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.